Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Zolpidem and Gender: Are Women Really At Risk?

Greenblatt DJ, Harmatz JS, Roth T.

J Clin Psychopharmacol. 2019 May/Jun;39(3):189-199. doi: 10.1097/JCP.0000000000001026.

PMID:
30939589
2.

Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid.

Matin B, Sherbini AA, Alam N, Harmatz JS, Greenblatt DJ.

J Pharm Pharmacol. 2019 Mar;71(3):371-378. doi: 10.1111/jphp.13037. Epub 2018 Nov 12.

PMID:
30417385
3.

Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety.

Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR.

J Clin Psychopharmacol. 2018 Aug;38(4):289-295. doi: 10.1097/JCP.0000000000000892.

PMID:
29851709
4.

Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety.

Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ.

J Clin Pharmacol. 2018 Nov;58(11):1436-1442. doi: 10.1002/jcph.1257. Epub 2018 May 11.

PMID:
29749631
5.

Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety.

Greenblatt DJ, Harmatz JS, Chow CR.

J Clin Psychopharmacol. 2018 Jun;38(3):172-179. doi: 10.1097/JCP.0000000000000861.

PMID:
29596146
6.

Update on Psychotropic Drug Prescribing in the United States: 2014-2015.

Greenblatt DJ, Harmatz JS, Shader RI.

J Clin Psychopharmacol. 2018 Feb;38(1):1-4. doi: 10.1097/JCP.0000000000000831. No abstract available.

PMID:
29215384
7.

Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR.

J Clin Pharmacol. 2018 Apr;58(4):533-540. doi: 10.1002/jcph.1040. Epub 2017 Nov 30.

PMID:
29194698
8.

Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers.

Court MH, Zhu Z, Masse G, Duan SX, James LP, Harmatz JS, Greenblatt DJ.

J Pharmacol Exp Ther. 2017 Sep;362(3):431-440. doi: 10.1124/jpet.117.242107. Epub 2017 Jun 29.

9.

Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls.

Elliott KR, Harmatz JS, Zhao Y, Greenblatt DJ.

J Athl Train. 2016 May;51(5):373-81. doi: 10.4085/1062-6050-51.5.14. Epub 2016 May 9.

10.

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Greenblatt DJ, Harmatz JS.

Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Epub 2015 Jun 1. Review.

11.

Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.

Zhao Y, Harmatz JS, Epstein CR, Nakagawa Y, Kurosaki C, Nakamura T, Kadota T, Giesing D, Court MH, Greenblatt DJ.

Br J Clin Pharmacol. 2015 Nov;80(5):1076-85. doi: 10.1111/bcp.12644. Epub 2015 Jun 8.

12.

Regression and Correlation.

Harmatz JS, Greenblatt DJ.

Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):161-2. doi: 10.1002/cpdd.200. No abstract available.

PMID:
27140795
13.

Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Harris SC, Kapil RP.

Drugs Aging. 2014 Oct;31(10):731-6. doi: 10.1007/s40266-014-0211-3.

PMID:
25246162
14.

Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ.

J Clin Pharmacol. 2014 Oct;54(10):1180-7. doi: 10.1002/jcph.317. Epub 2014 May 16. Erratum in: J Clin Pharmacol. 2014 Nov;54(11):1320.

15.

Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Epstein LC, Masse G, Harmatz JS, Scott TM, Papas AS, Greenblatt DJ.

Clin Rheumatol. 2014 Apr;33(4):511-21. doi: 10.1007/s10067-013-2453-6. Epub 2013 Dec 15.

PMID:
24337727
16.

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP.

J Clin Pharmacol. 2014 Mar;54(3):282-90. doi: 10.1002/jcph.220. Epub 2013 Nov 27.

PMID:
24203450
17.

Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets.

Greenblatt DJ, Harmatz JS, Singh NN, Roth T, Harris SC, Kapil RP.

J Clin Pharmacol. 2013 Nov;53(11):1194-8. doi: 10.1002/jcph.159. Epub 2013 Sep 6.

PMID:
23939537
18.

Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.

Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP.

Clin Ther. 2013 May;35(5):604-11. doi: 10.1016/j.clinthera.2013.03.007. Epub 2013 Mar 28. Erratum in: Clin Ther. 2013 Jun;35(6):900.

PMID:
23541711
19.

Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results.

Hanley MJ, Masse G, Harmatz JS, Court MH, Greenblatt DJ.

Clin Pharmacol Ther. 2012 Nov;92(5):651-7. doi: 10.1038/clpt.2012.170. Epub 2012 Oct 10.

20.

Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.

Hanley MJ, Masse G, Harmatz JS, Cancalon PF, Dolnikowski GG, Court MH, Greenblatt DJ.

Br J Clin Pharmacol. 2013 Apr;75(4):1041-52. doi: 10.1111/j.1365-2125.2012.04450.x.

21.

Mechanism-based inhibition of human cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content.

Greenblatt DJ, Zhao Y, Hanley MJ, Chen C, Harmatz JS, Cancalon PF, Gmitter FG Jr.

Xenobiotica. 2012 Dec;42(12):1163-9. doi: 10.3109/00498254.2012.700428. Epub 2012 Jul 18.

PMID:
22803802
22.

Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers.

Volak LP, Hanley MJ, Masse G, Hazarika S, Harmatz JS, Badmaev V, Majeed M, Greenblatt DJ, Court MH.

Br J Clin Pharmacol. 2013 Feb;75(2):450-62. doi: 10.1111/j.1365-2125.2012.04364.x.

23.

Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.

Greenblatt DJ, Harmatz JS, Walsh JK, Luthringer R, Staner L, Otmani S, Nedelec JF, Francart C, Parent SJ, Staner C.

Biopharm Drug Dispos. 2011 Dec;32(9):489-97. doi: 10.1002/bdd.773. Epub 2011 Sep 20.

PMID:
21935965
24.

Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily.

Reddy P, Ellington D, Zhu Y, Zdrojewski I, Parent SJ, Harmatz JS, Derendorf H, Greenblatt DJ, Browne K Jr.

Br J Clin Pharmacol. 2011 Sep;72(3):434-41. doi: 10.1111/j.1365-2125.2011.03996.x.

25.

Mechanism of cytochrome P450-3A inhibition by ketoconazole.

Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL.

J Pharm Pharmacol. 2011 Feb;63(2):214-21. doi: 10.1111/j.2042-7158.2010.01202.x.

PMID:
21235585
26.

Psychotropic drug prescribing in the United States: extent, costs, and expenditures.

Greenblatt DJ, Harmatz JS, Shader RI.

J Clin Psychopharmacol. 2011 Feb;31(1):1-3. doi: 10.1097/JCP.0b013e318209cf05. No abstract available.

PMID:
21192134
27.

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL.

Xenobiotica. 2010 Oct;40(10):713-20. doi: 10.3109/00498254.2010.506224. Review.

PMID:
20712450
28.

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH.

Br J Clin Pharmacol. 2009 Dec;68(6):920-7. doi: 10.1111/j.1365-2125.2009.03545.x.

29.

Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.

He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, Court MH.

Br J Clin Pharmacol. 2009 Nov;68(5):721-30. doi: 10.1111/j.1365-2125.2009.03519.x.

30.

The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial.

Ansell J, McDonough M, Zhao Y, Harmatz JS, Greenblatt DJ.

J Clin Pharmacol. 2009 Jul;49(7):824-30. doi: 10.1177/0091270009337510.

PMID:
19553405
31.

An irreverent look at the t test.

Harmatz JS.

J Clin Psychopharmacol. 2009 Apr;29(2):105-8. doi: 10.1097/JCP.0b013e31819d8925. No abstract available.

PMID:
19512970
32.

Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.

Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ.

Clin Pharmacol Ther. 2009 Jun;85(6):644-50. doi: 10.1038/clpt.2008.293. Epub 2009 Feb 25.

PMID:
19242403
33.

Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes.

Gan L, von Moltke LL, Trepanier LA, Harmatz JS, Greenblatt DJ, Court MH.

Drug Metab Dispos. 2009 Jan;37(1):90-6. doi: 10.1124/dmd.108.023424. Epub 2008 Oct 6.

34.

Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.

Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ.

Clin Pharmacol Ther. 2007 Jul;82(1):54-62. Epub 2007 Apr 18.

PMID:
17443132
35.

Fentanyl clearance and volume of distribution are increased in patients with major burns.

Han T, Harmatz JS, Greenblatt DJ, Martyn JA.

J Clin Pharmacol. 2007 Jun;47(6):674-80. Epub 2007 Apr 11.

PMID:
17428913
36.
37.

Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice.

Farkas D, Oleson LE, Zhao Y, Harmatz JS, Zinny MA, Court MH, Greenblatt DJ.

J Clin Pharmacol. 2007 Mar;47(3):286-94.

PMID:
17322140
38.

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T.

J Clin Psychopharmacol. 2007 Feb;27(1):28-34.

PMID:
17224709
39.

Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo.

Greenblatt DJ, Legangneux E, Harmatz JS, Weinling E, Freeman J, Rice K, Zammit GK.

J Clin Pharmacol. 2006 Dec;46(12):1469-80.

PMID:
17101746
40.

Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir.

Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ.

Clin Pharmacol Ther. 2006 Mar;79(3):243-54. Epub 2006 Feb 7.

PMID:
16513448
41.

Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate.

Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P.

J Clin Pharmacol. 2006 Feb;46(2):214-21.

PMID:
16432273
42.

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.

Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA.

Clin Pharmacol Ther. 2006 Jan;79(1):125-33.

PMID:
16413247
43.

Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration.

Greenblatt DJ, Blaskovich PD, Nuwayser ES, Harmatz JS, Chen G, Zinny MA.

J Clin Pharmacol. 2005 Nov;45(11):1288-93.

PMID:
16239362
44.

Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.

Culm-Merdek KE, von Moltke LL, Harmatz JS, Greenblatt DJ.

Br J Clin Pharmacol. 2005 Nov;60(5):486-93.

45.
46.

Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.

Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ.

J Clin Pharmacol. 2005 May;45(5):529-37.

PMID:
15831776
47.

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.

Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI.

Clin Pharmacol Ther. 2004 Nov;76(5):467-79.

PMID:
15536461
48.

Inhibition of human cytochromes P450 by components of Ginkgo biloba.

von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ.

J Pharm Pharmacol. 2004 Aug;56(8):1039-44.

PMID:
15285849
49.

Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.

Greenblatt DJ, Ehrenberg BL, Culm KE, Scavone JM, Corbett KE, Friedman HL, Harmatz JS, Shader RI.

J Clin Pharmacol. 2004 Jun;44(6):605-11.

PMID:
15145968
50.

Effect of age on in vitro triazolam biotransformation in male human liver microsomes.

Patki KC, von Moltke LL, Harmatz JS, Hesse LM, Court MH, Greenblatt DJ.

J Pharmacol Exp Ther. 2004 Mar;308(3):874-9. Epub 2003 Nov 21.

PMID:
14634046

Supplemental Content

Loading ...
Support Center